224 Views

VASCULAR

CCC

CCS

CSEM

CANVECTOR

DIABETES CANADA

DIABETE QUÉBEC

THROMBOSIS CANADA

VASCULAR

NURSING

GENERAL

ANGPTL3 INHIBITION

APOCIII INHIBITION

APPETITE REGULATION

ATP-CITRATE LYASE INHIBITOR

BEMPEDOIC ACID

COGNITIVE DECLINE

CVOT

DIABETES PREVENTION & REMISSION

DUAL AGONIST

DYSGLYCEMIA

DYSLIPIDEMIA

ENERGY EXPENDITURE

EVINACUMAB

GLP-1 RA AND GIP/GLP-1 RA DRUGS

GLUCOSE LOWERING & NEW INSULINS

HFPEF

INCLISIRAN

INCRETIN

LIPOPROTEIN (A) INHIBITORS

LOW DENSITY LIPOPROTEIN CHOLESTEROL

META-ANALYSIS

MI AND STROKE PREVENTION

MUVALAPLIN

NASH

NEW INCRETINS

OBESITY

OLPASIRAN

PCSK9 INHIBITORS

PELACARSAN

SAFETY

SGLT2 INHIBITOR DRUGS

THERAPY

TRIGYCERIDE-RICH LIPOPROTEIN CHOLESTEROL

TRIPLE AGONIST

TYPE 1 DIABETES

TYPE 2 DIABETES

FUTURE PHARMACOTHERAPY OPTIONS FOR VASCULAR DISEASE

FOCUS ON DYSLIPIDEMIA (VASC-120)

Friday, October 27, 2023

15:30 – 15:45 EST

Location: Palais, 516C

Presenter(s)

GM

G.B. John Mancini, MD, FRCPC, FACP, FACC (he/him/his)

Cardiologist
Centre for Cardiovascular Innovation, University of British Columbia
University of British Columbia

Disclosure(s):

G.B. John Mancini, MD, FRCPC, FACP, FACC: Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim/Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Esperion: Consultant/Advisory Board (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Ongoing)